Retaining Analysts Views in Focus: Synergy Pharmaceuticals (NASDAQ:SGYP), Exact Sciences (NASDAQ:EXAS)

Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) [Trend Analysis] try to make new thrust in street and making different trends, stocks trading ended with 2.71% to $6.26. The SGYP held a rough session during the week but was ready to get some critical analysis. The stock was assessed by a pool of analysts at WSJ and came out with some serious outcomes not to be avoided before making investment. The SGYP ratings chart showed that 1 gave HOLD ratings for the current month. For stocks’ current month, 4 analysts opted for BUY ratings. The stock price target chart showed average price target of 10.80 as compared to current price of 6.68.

Taking look on per share earnings estimates, its next year first quarter current estimate trend for EPS was for $-0.16 and on annual basis FY 2016 estimate trends at current was for $-0.98 as compared to one month ago of $-1, and for next year per share earnings estimates have $-0.45.

The share price of SGYP attracts active investors, as stock price of week volatility recorded 6.91%. The stock is going forward to its 52-week low with 150.20% and lagging behind from its 52-week high price with -0.56%.

Exact Sciences Corporation (NASDAQ:EXAS) [Trend Analysis] surged reacts as active mover, shares an increase 0.37% to traded at $13.41 and the percentage gap between open changing to regular change was 1.87%. Lets us look over what analysts have to say about performance of the EXAS. Starting with EPS for the final quarter of this year. EPS is usually the indicator of profitability for the company. According to WSJ analysis, the Q4 2016 current estimates trends were for $-0.41 as compared to the next year Q1 current trend of $-0.40. While on annual basis the current EPS estimates trend for FY 2017 came in for $-1.45 as compared to three months ago $-1.45.

The stock prices target chart showed high target of 26 kept by analysts at WSJ while the average price target was for 19.60 as compared to current price of 14.95. Somehow, the stock managed to gain BUY ratings by 5 analysts in current tenure as 1 analyst having overweight ratings, 6 recommend as HOLD. Overall, the consensus ratings were for Overweight by the pool of analysts.

The firm’s current ratio calculated as 11.90 for the most recent quarter. The firm past twelve months price to sales ratio was 18.66 and price to cash ratio remained 4.34. As far as the returns are concern, the return on equity was recorded as -55.40% and return on investment was -47.80% while its return on asset stayed at -49.30%. The firm has total debt to equity ratio measured as 0.02.


About Richard Avery

He is a capital projects manager and process design engineer at a large-cap company. He has renowned MBA degree. Before joining SWR, he was a freelance writer for renounce tech websites. He is currently studying for CFP exam. Interests: Tech stocks, Economic Markets, Blue-chips.

Leave a Reply

Your email address will not be published. Required fields are marked *